Researchers have developed a tool to help make treatment decisions for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPE).1
Findings showed that CT improved overall nocturia, voiding, and storage symptoms compared with DUT or TAM therapy in most patient profiles.
This tool uses clinical covariates to measure storage, voiding, and nocturnal frequency in patients receiving placebo, dutasteride (Avodart, DUT), tamsulosin (Flomax, TAM), or DUT/TAM combination therapy (CT). Predict changes in urine LUTS. Data on the predictive model were presented at his 2023 American Urological Association Annual Meeting in Chicago, Illinois.
The results were presented by first author Klaus Rollborn, M.D., Ph.D., who described the model as follows: and placebo, over 4 years. The nomogram employs these patients’ baseline His parameters along with all inclusion parameters that are closely related to these studies. [prostate-specific antigen] Create nomograms to predict changes in characteristic symptom flow, prostate size, and PSA inclusion, and symptom score greater than 1.5. Roehrborn is her EE Fogelson and Greer Garson Fogelson Distinguished Chair in Urology and the ST Harris Family Chair in Medical Sciences in honor of John D. McConnell, MD, at the University of Texas Southwestern Medical Center in Dallas.
Baseline characteristics used by the tool to predict outcome were age, International Prostate Symptom Score, total prostate volume (PV), peak urine flow (Qmaximum), PSA, postvoid residual urine (PVR), alpha-blocker (AB) use within 12 months, and randomized treatment.
Findings showed that CT improved overall nocturia, voiding, and storage symptoms compared with DUT or TAM therapy in most patient profiles. Features predictive of worsening cumulative symptoms were older age, higher PVR, and her previous AB treatment. Features associated with worsening micturition and nocturia symptoms included higher PVR and lower Q at baseline.maximum.
Patients with high PSA and PV values had significantly improved DUT outcomes compared to placebo. Higher PSA predicted greater improvement in nocturia among all treatments. High Qmaximum Levels showed improvements in nocturia and voiding scores with all treatments.
Roehrborn concludes: [their] mind etc. [this tool is] It’s a convenient way to actually see how the parameters affect the results. “
reference
1. Roehrborn C, Manuel Palacios-Moreno J, Chavan C, et al. Storage vs. Effect of Treatment on Voiding Symptoms and Nocturia Frequency: A Dynamic Nomogram N = 9167 men with BPH. Presented at: American Urological Association Annual Meeting, April 28-May 1, Chicago. Abstract LBA01-02